Showing 3341-3350 of 5910 results for "".
- Opus Genetics Announces Two Leadership Appointmentshttps://modernod.com/news/opus-genetics-announces-two-leadership-appointments/2480367/Opus Genetics announced two key appointments to its founding executive team. Ash Jayagopal, PhD, has joined the company as Chief Scientific Officer (CSO); and Joe Schachle has joined as Chief Operating Officer (COO). “We were thrilled to launch Opus last month to advance an A
- Prevent Blindness: Senate FY2022 Appropriations Bill Doubles Funding for the CDC’s Vision and Eye Health Programhttps://modernod.com/news/prevent-blindness-senate-fy2022-appropriations-bill-doubles-funding-for-the-cdcs-vision-and-eye-health-program/2480364/This week, the Senate Appropriations Committee released its proposed legislation to fund programs under the Department of Health and Human Services in Fiscal Year (FY) 2022. "As a result of continued Prevent Blindness advocacy efforts, the Senate Appropriations legislation includes
- Retrotope Reports Positive Results from Studies of RT011 in Animal Models of Retinal Degenerationhttps://modernod.com/news/retrotope-reports-positive-results-from-studies-of-rt011-in-animal-models-of-retinal-degeneration/2480361/Retrotope announced that positive results from preclinical studies of RT011, the second compound to emerge from the company’s novel technology platform, are being reported
- Atsena Therapeutics Unveils XLRS Gene Therapy Program Leveraging Novel Spreading Capsidshttps://modernod.com/news/atsena-therapeutics-unveils-xlrs-gene-therapy-program-leveraging-novel-spreading-capsids/2480355/Atsena Therapeutics unveiled its preclinical gene therapy program for X-linked retinoschisis (XLRS), a monogenic disease caused by mutations in the RS1 gene. XLRS is characterized by schisis, or abnormal splitting of the layers of the retina, which causes impa
- New 4-Year Data Show Genentech’s Enspryng Significantly Reduces Debilitating Relapses in People with NMOSDhttps://modernod.com/news/new-4-year-data-show-genentechs-enspryng-significantly-reduces-debilitating-relapses-in-people-with-neuromyelitis-optica-spectrum-disorder/2480350/Genentech announced new longer-term efficacy and safety data for Enspryng (satralizumab-mwge). The data show Enspryng has a favorable benefit-risk profile and is effective in reducing relapses over 4 years of treatment in people with anti-aquaporin-4 antibody (AQP4-IgG) seropositive NMOSD, a
- Clearside Biomedical Delivers Podium and Poster Presentations at ASRS Annual Meetinghttps://modernod.com/news/clearside-biomedical-delivers-podium-and-poster-presentations-at-asrs-annual-meeting/2480347/Clearside Biomedical announced that multiple presentations were given at the American Society of Retina Specialists (ASRS) Annual Meeting and at the OIS Retina Summit at ASRS, which took place October 7-12, 2021 in San Antonio, Texas. “The data pres
- AsclepiX Appoints Amir Shojaei, PhD, as Chief Scientific Officer and Executive Vice President, Clinical Developmenthttps://modernod.com/news/asclepix-appoints-dr-amir-shojaei-as-chief-scientific-officer-and-executive-vice-president-clinical-development/2480336/
- CooperVision Specialty EyeCare Launches New Mobile Application for Paragon CRT and Dual Axis Contact Lens Fittinghttps://modernod.com/news/coopervision-specialty-eyecare-launches-new-mobile-application-for-paragon-crt-and-dual-axis-contact-lens-fitting/2480314/CooperVision Specialty EyeCare launched its innovative Paragon CRT Calculator mobile application for eye care professionals (ECPs). The multifunctional app includes several features aimed at simplifying the fitting process for CRT and CRT
- Monica Jong, PhD, Appointed Global Professional Education Lead, Myopia at Johnson & Johnson Visionhttps://modernod.com/news/monica-jong-phd-appointed-global-professional-education-lead-myopia-at-johnson-johnson-vision/2480309/Monica Jong, PhD, co-founder of the
- Nicox’s NCX 470 Shows Retinal Cell Protection in a Nonclinical Modelhttps://modernod.com/news/nicoxs-ncx-470-shows-retinal-cell-protection-in-a-nonclinical-model/2480307/Nicox reported new data on NCX 470 in a nonclinical model of retinal cell damage induced by endothelin-1 (ET-1). NCX 470, Nicox’s lead clinical candidate, is a nitric oxide-donating prostaglandin analog currently in phase 3 clinical development for lowering IOP in patients with op